Arecor Therapeutics PLC (AIM:AREC) has appointed Dr Helen Parris as senior vice president, commercial and general manager of its subsidiary Tetris Pharma, effective 15 January.
Parris brings over two decades of experience in the biopharmaceutical sector, including roles in scientific, commercial and government affairs.
She joins from Albireo Pharma, where she held the role of general manager, Northern Markets and helped launch the business' first product. Parris also occupied key positions at Gilead, the American biotechnology giant. Her academic background includes a BSc in Biology, a PhD, and an MBA.
"Helen's proven track record in bringing products to market and growing sales will be key as we continue the roll-out of Ogluo across the UK and Europe," said Sarah Howell, Arecor's chief executive.
"Ogluo is an important treatment for people with diabetes and their caregivers that can provide them with the confidence to manage severe hypoglycaemic events and, under Helen's leadership, Tetris Pharma is even better positioned for the continued adoption of this key product in a c.£100 million market.
"Not only will this deliver a revenue stream but a successful commercial distribution platform through Tetris Pharma is highly complementary to our existing specialty hospital products business and has significant growth potential, providing Arecor with the capability to take selected products to market in the UK and Europe."